research Complete responses and SALT zero scores in alopecia areata: not the same
Significant hair regrowth doesn't always mean complete hair recovery in alopecia areata.
Search
for
Sort by
Research
210-240 / 1000+ resultsresearch Twelve‐point scale grading system of scanning electron microscopic examination to investigate subtle changes in damaged hair surface
The 12-point scale is better for evaluating small changes in hair condition after using hair care products.
research 5ARI and PSA: open questions
5ARI treatment improves PSA test accuracy for prostate cancer diagnosis.
research P64 Efficacy of baricitinib in patients with different degrees of severe alopecia areata: 52-week results from BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
research Alopecia areata incognita: clinical characteristics and use of the Sinclair shedding scale
The Sinclair Shedding Scale is effective for diagnosing Alopecia Areata Incognita and monitoring treatment success.
research Efficacy of modern methods for assessing the severity of alopecia areata
The SBN system effectively assesses alopecia areata severity and predicts its course.
research 598 Response to ritlecitinib treatment based on salt improvement scores in patients with alopecia areata (AA): Post hoc analysis of the allegro phase 2b/3 study
Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.
research Measures of Adult Systemic Lupus Erythematosus: Disease Activity and Damage
Choosing the right tools is crucial for accurately measuring lupus activity and damage.
research Validation of a skin and coat scoring protocol in dogs
The protocol is easy to use, but reliable results need the same person to assess each time.
research Systemic Inflammatory Biomarkers in Alopecia Areata: The Role of SII, SIRI, and CRP/Albumin Ratio
Alopecia areata patients have higher systemic inflammation, even in mild cases.
research 667 Patient satisfaction with a multidisciplinary alopecia areata group medical visit
Patients were very satisfied with the multidisciplinary group visit for alopecia areata.
research Board Certification - ABHRS
The document's conclusion cannot be determined from the provided text.
research A Critical Evaluation of Evaluations for Long-form Question Answering
Current automatic metrics for long-form question answering don't align with human preferences; a multi-faceted evaluation approach is needed.
research Signposts to the Promised Land in Alopecia Areata
Patient-reported outcomes better reflect the quality of life impact of alopecia areata than traditional severity scores.
research Assessment of the Mean Platelet Volume-to-Platelet Count Ratio in Alopecia Areata: A Retrospective Case Control Study
The MPV/PC ratio can help assess disease activity in alopecia areata.
research Effectiveness and safety of baricitinib in severe alopecia areata: 48‐week results
Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
research The Importance of Readability: A Guide to Understanding Alopecia Areata through Multilingual Online Resources
Online articles about alopecia areata are too hard to understand and need to be clearer.
research Association between air quality index and risk of alopecia areata: A nationwide population-based cohort study
Higher air pollution increases the risk of alopecia areata.
research Scoring systems for pemphigus
The Pemphigus Disease Area Index and Autoimmune Bullous Skin Disorder Intensity Score are the best tools for assessing pemphigus severity.
research Quality of life measurement in alopecia areata. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes
Use specific tools to measure quality of life in alopecia areata patients and improve future treatments.
research ISHRS Best Practices Survey Project MODULE: Anesthesia and Emergency SUMMARY ANALYSIS
research SALT score distribution with ritlecitinib treatment up to 24 months in alopecia areata
Ritlecitinib improves hair regrowth in alopecia areata over 24 months.
research Effectiveness of baricitinib in severe alopecia areata in real life: a retrospective study of 87 patients
Baricitinib is effective and safe for treating severe alopecia areata.
research Review of Baricitinib in the Treatment of Alopecia Areata.
Baricitinib is a relatively safe and effective treatment for severe alopecia areata.
research The Independent Internet Marketing Site: A Symbiotic Confederation?
The document's conclusion cannot be provided because the document is not accessible or understandable.
research Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review
Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
research An Evaluation System to Enhance Patient Selection for Alopecia-Reducing Surgery
The evaluation system improved patient selection for hair loss surgery, leading to better results and satisfaction.
research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
research 1419 Pre-clinical in-vitro assays for high throughput screening of drug candidates for protection and restoration of immune privilege in alopecia areata
The research developed methods to test drugs that could protect and restore hair follicle protection in a hair loss condition.
research 53274 Real-world experience of efficacy and safety of baricitinib in Korean patients with severe alopecia areata
Baricitinib 4 mg is effective and safe for treating severe alopecia areata.